The overlap of interstitial cystitis/painful bladder syndrome and overactive bladder

Journal of the Society of Laparoendoscopic Surgeons

Volumn 14, Issue 1, 2010, Pages 83-90

  Chung, Maurice K ^a   Butrick, Charles W ^b   Chung, Cherie W ^a  

^a Midwest Regional Center for Chronic Pelvic Pain   (United States)

^b Midwest Regional Center for Chronic Pelvic Pain   (United States)

Author keywords

Cystoscopy; Hydrodistention; Interstitial cystitis painful bladder syndrome; Overactive bladder; Potassium sensitivity test

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CYSTOSCOPY; FEMALE; HUMAN; INTERSTITIAL CYSTITIS; MALE; MIDDLE AGED; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; URINE INCONTINENCE; URODYNAMICS;

ADOLESCENT; ADULT; CYSTITIS, INTERSTITIAL; CYSTOSCOPY; FEMALE; HUMANS; MALE; MIDDLE AGED; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE; URODYNAMICS; YOUNG ADULT;

EID: 77954560654     PISSN: 10868089     EISSN: 19383797     Source Type: Journal    
DOI: 10.4293/108680810X12674612014743     Document Type: Article

References (31)

1. Abrams P, Cardozo L, Fall M, et al. The standardization of terminology of lower urinary tract function: report from the Standardization Subcommittee of the International Continence Society. Neurourol Urodyn. 2002;21:167.
2. Association of Reproductive Health Professionals. Interstitial Cystitis Association. Outcome of the Washington, DC consensus meeting on interstitial cystitis/painful bladder syndrome: a multidisciplinary meeting of researchers, clinicians, and patients. Washington, DC Consensus Group on IC/PBS. February 10, 2007.
3. Jones CA, Nyber L. Epidemiology of interstitial cystitis. Urology. 1997;49(5a):2-9.
4. Parsons CL, Dell J, Stanford E, et al. Increased prevalence of interstitial cystitis: previously unrecognized urologic and gynecologic cases identified using a new symptom questionnaire and intravesical potassium sensitivity. Urology. 2002;60:573-578.
5. Abrams P, Wein AJ. Correspondence Urology. 1998;51:1062.
6. Nishizawa O. Discussion: assessment of symptoms in patients with an overactive bladder. Urology. 1997;50(suppl 6A):23.
7. Abrams P, Wein AJ. The Overactive Bladder: A Widespread and Treatable Condition. Stockholm, Sweden: Erik Sparre Medical AB; 1998.
8. Clinical Practice Guidelines: Urinary Incontinence in Adults. 1996. AHCPR publication 96-0682.
9. Parsons CL, Zupkas P, Parsons JK. Intravesical potassium sensitivity in patients with interstitial cystitis and urethral syndrome. Urology. 57:428-432, 2001; discussion 432-433.
10. Wein AJ, Rovner ES. The overactive bladder: an overview for primary care health providers. Int J Fertil. 1999;44(2):56-66.
11. Parsons CL, Bullen M, Kahn BS, et al. A gynecologic presentation of interstitial cystitis as detected by intravesical potassium sensitivity. Obstet Gynecol. 2001;98:127-132.
12. Koziol JA. Epidemiology of interstitial cystitis. Urol Clin North Am. 1994;21(1):7-20.
13. Rosamilia A, Dwyera PL. Pathophysiology of interstitial cystitis. Curr Opin Obstet Gynecol. 2000;12:405-410.
14. Wesselmann U. Interstitial cystitis as a visceral pain syndrome. Urology. 2001;51(suppl 6):102.
15. Cervero F. Sensory innervation of the viscera: peripheral basis of visceral pain. Physiol Rev. 1994;74:95-138.
16. Mayer EA. Clinical implications of visceral hyperalgesia. Contemp Intern Med. 1994;46:42-54.
17. Markenson J. Mechanisms of chronic pain. Am J Med. 1996; 101(suppl 1a):6s-18s.
18. Coderre P, Katz J, Vaccarino A, Melzack R. Contribution of central neuroplasticity to pathologic pain: review of clinical and experimental medicine. Pain. 1993;52:259-285.
19. Woolf CJ. Evidence for a central component of post heightened injury pain hypersensitivity. Nature. 1983;306:686.
20. de Groat WC, Downie JW, Levin RM, et al. Basic neurophysiology and neuropharmacology In: Abrams P, Khoury S, eds. Incontinence: First International Consultation on Incontinence. Plymouth, United Kingdom: Health Publications; 1999.
21. Steers WD. Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol. 2002;4(suppl 4):S7-S18.
22. de Groat WC. The urothelium in overactive bladder: passive bystander or active participant? Urology. 2004;64(suppl 1):7-11.
23. Abrams P, Khoury S, Wein A, et al, eds. Incontinence: First International Consultation on Incontinence. Plymouth, United Kingdom. Plymbridge Distributors Ltd. 1999;105-154.
24. Chambers GK, Fenster HN, Cripps S, et al. An Assessment of the Use of Intravesical Potassium in the Diagnosis of Interstitial Cystitis. J Urol. 1999;162:699-701.
25. Parsons CL, Forrest J, Nickel JC, et al. Effect of Pentosan Polysulfate Therapy on Intravesical Potassium Sensitivity. Urology. 2002;59:329-333.
26. Pelman RS, Capo JP, Forero-Schwanhaeuser S. Solifenacin at 3 years: a review of efficacy and safety. Postgrad Med. 2008; 120(2):86-92.
27. Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology. 2001;57:414-421.
28. Nitti VW, Dmochowski R, Sand PS, et al. Efficacy, safety and tolerability of Fesoterodine for overactive bladder syndrome. J Urol. 2007;178(6):2488-2494.
29. Gauruder-Burmester A, Popken G. Follow-up at 24 months after treatment of overactive bladder with 0.2% sodium chrondroitin sulfate. Aktuelle Urol. 2009;40(6)355-359.
30. Chiang G, Patra P, Letourneau R, et al. Pentosanpolysulfate inhibits mast cell histamine secretion and intracellular calcium ion levels: an alternative explanation of its beneficial effect in interstitial cystitis. J Urol. 2000;164:2119-2125.
31. Yoshimura N, Satoshi S, Chancellor MB, de Groat WC. Targeting afferent hyperexcitability for therapy of the painful bladder syndrome. Urology. 2002;59(suppl 5A):61-67.